How OSTHUS reduced risk in vaccine manufacturing by 6%

  • Manufacturing at risk, or before the prevalent influenza strain is known
  • Maintain vaccine effectiveness by predicting influenza variants about a year in advance
  • Prevent hospitalizations, deaths, and other costs of annual influenza viruses
  • Predictive models that use data to make quantitative influenza predictions
  • Proactive vaccine manufacturing using advanced analytics
  • Ability to manufacture vaccines ahead of the season
  • Data-driven decision-making to improve public health and disease control
  • Improved predictive accuracy by 6% and reduced manufacturing risk, subsequently saving millions of dollars per year
Michael Moskal II
Director of US Operations
Rachel Wilson
Former Content Writer
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram